References
AlAmeri M, Epstein M, Johnston A. Generic and therapeutic substitutions: are they always ethical in their own terms? Pharm World Sci. 2010;32(6):691–5.
Plans-Rubio P. The cost effectiveness of statin therapies in Spain in 2010, after the introduction of generics and reference prices. Am J Cardiovasc Drugs. 2010;10(6):369–82.
Kohl H, Shrank WH. Increasing generic drug use in Medicare Part D: the role of government. J Am Geriatr Soc. 2007;55(7):1106–9.
Davit BM, Nwakama PE, Buehler GJ, Conner DP, Haidar SH, Patel DT, et al. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration. Ann Pharmacother. 2009;43(10):1583–97.
Kesselheim AS, Stedman MR, Bubrick EJ, Gagne JJ, Misono AS, Lee JL, et al. Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis. Drugs. 2010;70(5):605–21.
Gagne JJ, Avorn J, Shrank WH, Schneeweiss S. Refilling and switching of antiepileptic drugs and seizure-related events. Clin Pharmacol Ther. 2010;88(3):347–53.
Author information
Authors and Affiliations
Corresponding author
Additional information
The author holds the EGA chair ‘European policy towards generic medicines’.
Rights and permissions
About this article
Cite this article
Simoens, S. Generic and therapeutic substitution: ethics meets health economics. Int J Clin Pharm 33, 469–470 (2011). https://doi.org/10.1007/s11096-011-9500-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11096-011-9500-7